Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis-Authors' reply

Lukas Burghart; Benedikt Silvester Hofer; Emina Halilbasic; Benedikt Simbrunner; Albert Friedrich Staettermayer; Michael Trauner; Thomas Reiberger

doi:10.1111/apt.18067

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis-Authors' reply

Aliment Pharmacol Ther. 2024 Jul;60(1):107-108. doi: 10.1111/apt.18067. Epub 2024 May 27.

Authors

Lukas Burghart^{1

2}, Benedikt Silvester Hofer^{2

3

4}, Emina Halilbasic^{2

3}, Benedikt Simbrunner^{2

3

4}, Albert Friedrich Staettermayer^{2

3

4}, Michael Trauner^{2

3}, Thomas Reiberger^{2

3

4}

Affiliations

¹ Klinik Ottakring, Wiener Gesundheitsverbund, Vienna, Austria.
² Rare Liver Diseases (RALID) Center of the ERN RARE-LIVER at the Vienna General Hospital, Vienna, Austria.
³ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
⁴ Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

PMID: 38803242
DOI: 10.1111/apt.18067

No abstract available

Publication types

Letter
Comment

MeSH terms

Cholangitis / drug therapy
Fibric Acids / therapeutic use
Humans
Hypolipidemic Agents / adverse effects
Hypolipidemic Agents / therapeutic use
Liver Cirrhosis* / complications
Liver Cirrhosis* / drug therapy
Liver Cirrhosis, Biliary / complications
Liver Cirrhosis, Biliary / drug therapy

Substances

Hypolipidemic Agents
Fibric Acids